Souhaitez-vous accéder aux communiqués récents ?

TORONTO, 02 avr. 2026 (GLOBE NEWSWIRE) -- Crohn et Colite Canada et AbbVie sont heureux d'annoncer l'ouverture des candidatures pour le Programme de bourses d'études MII d’AbbVie 2026. Cette année...

Crohn’s and Colitis Canada and AbbVie open applications for the 2026 AbbVie IBD Scholarship, marking 15 years of supporting students living with IBD.

New York, March 03, 2026 (GLOBE NEWSWIRE) -- [New York, NY, and Riyadh, Saudi Arabia [March 3, 2026] — Mount Sinai and King Saud University Medical City in Riyadh, Saudi Arabia, today announced a...

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of...

Belleville, Illinois, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...

HORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology...

Yaqrit progresses novel treatment into pilot study for primary sclerosing cholangitis and IBD. Results expected H2 2026

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely...

Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract...